Trial Information
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
Sponsor: Mirati Therapeutics, Inc. PRA Health Sciences
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724
